(Q37226376)

19 August 2017

1 reference

title

Schizophrenia, obesity, and antipsychotic medications: what can we do? (English)

1 reference

19 August 2017

0 references

0 references

Leslie Citrome

1

1 reference

PubMed ID

18654065

19 August 2017

Betty Vreeland

series ordinal

2

1 reference

PubMed ID

18654065

19 August 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

19 August 2017

Postgraduate Medicine

1 reference

19 August 2017

120

1 reference

19 August 2017

2

1 reference

19 August 2017

18-33

1 reference

The disease burden associated with overweight and obesity

19 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Latest therapies for bipolar disorder. Looking beyond lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Atypical antipsychotics: revolutionary or incremental advance?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Evaluation of obesity. Who are the obese?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Metabolic syndrome and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

The obesity epidemic, metabolic syndrome and future prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Prevalence of overweight and obesity in the United States, 1999-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Early predictors of substantial weight gain in bipolar patients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Body weight changes associated with psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A program for managing weight gain associated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A program for treating olanzapine-related weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Cognitive behavioural therapy for weight gain associated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Weight loss with psychiatric residents in a behavioral self control program

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Commercial and self-help programs for weight control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Interventions to reduce weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Amantadine for weight gain associated with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Nizatidine for the treatment of patients with quetiapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

Surgical treatment of morbid obesity in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1786

21 January 2018

Identifiers

DOI

10.3810/PGM.2008.07.1786

1 reference

19 August 2017

1 reference

PubMed ID

18654065